June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Pharmacokinetics and Local Tolerability of Cyclodextrin-based Angiotensin-Receptor Antagonist eye drops in rabbits
Author Affiliations & Notes
  • Gerhard Garhofer
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
  • Martin Kallab
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
  • Kornelia Schutzenberger
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria
  • Bhavapriya Schäfer
    Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria
  • Aimin Tan
    Bioanalytical Laboratory Nucro-Technics, Ontario, Canada
  • Phatsawee Jansook
    Faculty of Pharmaceutical Sciences, Chulalongkorn University, Thailand
  • Markus Zeitlinger
    Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
  • Laura Lorenzo-Soler
    University of Iceland, Iceland
  • Einar Stefánsson
    University of Iceland, Iceland
  • Footnotes
    Commercial Relationships   Gerhard Garhofer, None; Martin Kallab, None; Kornelia Schutzenberger, None; Bhavapriya Schäfer, None; Aimin Tan, None; Phatsawee Jansook, None; Markus Zeitlinger, None; Laura Lorenzo-Soler, None; Einar Stefánsson, Oculis (I)
  • Footnotes
    Support  European Union’s programme Eurostar under the project No PREVIN E11008
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 32. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gerhard Garhofer, Martin Kallab, Kornelia Schutzenberger, Bhavapriya Schäfer, Aimin Tan, Phatsawee Jansook, Markus Zeitlinger, Laura Lorenzo-Soler, Einar Stefánsson; Pharmacokinetics and Local Tolerability of Cyclodextrin-based Angiotensin-Receptor Antagonist eye drops in rabbits. Invest. Ophthalmol. Vis. Sci. 2020;61(7):32.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Cyclodextrin nanoparticles have been shown to increase bioavailability of poorly water-soluble drugs and may therefore serve as an option for drug delivery to the back of the eye. The current study was performed to investigate the ocular pharmacokinetics (PK) and local tolerability of the two newly developed γ-cyclodextrin based angiotensin receptor antagonist formulations , cyclodextrin-irbesartan 1.5% and cyclodextrin-candesartan 0.15%.

Methods : 59 rabbits were included in the PK study. For both drugs, single and multiple dose PK were performed: Single dose rabbits (n=49) were euthanized 0.5, 1.5, 3, 6 or 12 hours-post dose, whereas multiple dose animals (n=10) were dosed for 5 days twice daily before euthanisation. Analysis was done using LC-MS/MS. PK parameters including maximal drug concentration (Cmax) and time of maximal drug concentrations (Tmax) were calculated for aqueous humor (AH) and retinal tissue/choroid (RT). Local tolerability of cyclodextrin-irbesartan 1.5% eye drops was assessed using a modified Draize scale after twice daily administration for 28 days in a different group of 5 animals.

Results : Single dose irbesartan administration led to a RT Cmax of 251±143ng/g at 0.5 hours whereas in the AH a Cmaxof 121±69ng/g was reached at 3 hours post instillation. For single dose candesartan, RT Cmax was 63±39ng/g at 0.5 hours after application. AH reached a Cmax of 30±14ng/g at the 3 hours time point for candesartan. For multiple dosing mean RT concentration reached 338±124ng/g for irbesartan and 36±10ng/g for candesartan, whereas mean AH concentrations were 231±68ng/g and 70±22ng/g, respectively. Local tolerability during the 28 day treatment period was good.

Conclusions : The present data shows good local tolerability and high tissue concentration in the retina, showing the potential of cyclodextrin nanoparticles for drug delivery to the posterior pole of the eye.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×